Adoptive T-cell transfer in cancer immunotherapy

Siok Keen Tey, Catherine M. Bollard, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Adoptive T-cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein-Barr virus-associated post-transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self-antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour-evasion strategies. Adoptive immunotherapy presents the opportunity to activate, expand and genetically modify T cells outside the tolerising environment of the host and a number of strategies to optimize the cellular product, including gene modification and modulation of the host environment, in particular by lymphodepletion, have been developed.

Original languageEnglish (US)
Pages (from-to)281-289
Number of pages9
JournalImmunology and Cell Biology
Issue number3
StatePublished - Jun 2006


  • Adoptive immunotherapy
  • Bone marrow transplantation
  • Gene therapy
  • Neoplasm
  • T lymphocyte

ASJC Scopus subject areas

  • Immunology
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Adoptive T-cell transfer in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this